Caroline Coats

Oregon Health & Science University — United States

Medicine · Health Sciences

27h-index2.2kcitations133works10.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiomyopathy and Myosin Studies(63), Cardiovascular Function and Risk Factors(37), Cardiovascular Effects of Exercise(24), Congenital Heart Disease Studies(14), Viral Infections and Immunology Research(11)

Publications130 total

EPH121 Healthcare Resource Use in Transthyretin Amyloidosis Cardiomyopathy: An Observational Study in the UK Clinical Setting Using Electronic Health Records
Value in Health·2025
Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Circulation Heart Failure·2025Open Access
Abstract 4361884: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
Circulation·2025
Abstract 4336093: Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy
Circulation·2025
Abstract 4370461: Aficamten is safe and effective in oHCM with comorbidities obesity, hypertension, and diabetes: a SEQUOIA-HCM sub-study
Circulation·2025
The incidence of death and risk factors for mortality in cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records
European Heart Journal·2025
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma
JACC CardioOncology·2025· 2 citedOpen Access
Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials
Progress in Cardiovascular Diseases·2025· 4 citedOpen Access
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
Circulation·2025· 1 citedOpen Access
Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials
Heart Rhythm·2025· 1 citedOpen Access
1-026 Evaluating the pathogenic potential of a variant of unknown significance in filamin C
2025Open Access
1-036 RIDGE <sup>TM</sup> -1: a phase 1b interventional study to evaluate safety and efficacy of TN-401, an adeno-associated virus serotype 9 (AAV9) investigational gene therapy, in adults with <i>PKP2</i> -associated arrhythmogenic right ventricular cardiomyopathy (ARVC)
2025Open Access
1-016 Evaluating the concordance of ATTR amyloidosis recording between primary and secondary care electronic healthcare data using general practice survey feedback
2025Open Access
Implementation of the Ottawa morbidity and mortality model improves the quality of morbidity and mortality rounds
American Journal of Veterinary Research·2025Open Access
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
JACC Heart Failure·2025· 9 citedOpen Access
British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of adult patients with obstructive hypertrophic cardiomyopathy receiving myosin-inhibitor therapy
Echo Research and Practice·2025Open Access
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial
European Heart Journal·2025· 4 citedOpen Access
Transcatheter Amplatz canine duct occluder placement for patent ductus arteriosus occlusion: a retrospective analysis of outcomes and complications in 200 dogs
Journal of Veterinary Cardiology·2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
JACC Heart Failure·2025· 1 citedOpen Access
PO-05-115 DETERMINING ELIGIBILITY FOR RIDGETM-1, A PHASE 1B INTERVENTIONAL STUDY TO EVALUATE SAFETY AND EFFICACY OF TN-401 GENE THERAPY IN ADULTS WITH PLAKOPHILIN-2 (PKP2)-ASSOCIATED ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC): INTERIM RESULTS OF AN OBSERVATIONAL STUDY TO ASSESS SEROPREVALENCE TO ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9)
Heart Rhythm·2025Open Access
page 1 of 7Next →

Frequent Co-authors

Perry Elliott(19), Martin S. Maron(18), Ahmad Masri(16), Iacopo Olivotto(16), Anjali Owens(16), Stuart Kupfer(16), Fady I. Malik(16), Lisa Meng(16), Scott D. Solomon(15), Amy Wohltman(15), Stephen B. Heitner(14), Roberto Barriales‐Villa(12), Lubna Choudhury(12), Hugh Watkins(12), Daniel Jacoby(12), Theodore P. Abraham(11), Pablo García‐Pavía(10), Matthew M.Y. Lee(8), Sara Saberi(8), Florian Rader(8)